Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1Anemia 1

Interventions

fludarabine 10Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Tacrolimus 5Mycophenolic Acid 5Melphalan 5Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Busulfan 4AP 1903 reagent 4thymoglobulin 3Sirolimus 3Cord Blood Stem Cell Transplantation 3Alemtuzumab 3Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Platelet Transfusion 2Meropenem 2Cyclosporine 2Biopsy 2Antilymphocyte Serum 2visilizumab 1venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Blood Component Transfusion × Classical hematology × Clear all
NCT03086252 2018-07-26

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

Emory University

Phase NA Withdrawn
Classical hematologyMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Anemia, Aplastic, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡